Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Hydrix (HYD) successfully completes its first commercial implant of the Guardian device in the US
  • The procedure was performed last week by cardiac electrophysiologist and cardiologist Dr Andrew J Kaplan
  • The Guardian device uses machine learning algorithms and artificial intelligence to continuously monitor the patient’s heart signal
  • Hydrix has also completed the application to the Australian Therapeutic Goods Administration and expects to receive approval in the first half of 2022
  • Hydrix has ended the day 9.68 per cent in the green with shares trading at 17 cents

Hydrix (HYD) has successfully completed its first commercial implant of the Guardian device in the US.

The procedure was performed last week by cardiac electrophysiologist and cardiologist Dr Andrew J Kaplan of Cardiovascular Associates of Mesa in Arizona.

Dr Kaplan is pleased with the success and outcome of the procedure.

“The first commercial implant of the Guardian marks a pivotal advancement in cardiac care. The device detects impending acute coronary syndrome (ACS) events including silent heart attacks, and leads to earlier patient treatment,” Dr Kaplan commented.

“Given the device’s clinical success, the cardiovascular community can feel confident in this new, first-in-kind technology.”

Hydrix’s Guardian device uses machine learning algorithms and artificial intelligence to continuously monitor the patient’s heart signal and warn of any coronary syndromes such as silent heart attacks.

General Manager Paul Kelly commented on the significant milestone.

“Today’s announcement about the first USA commercial Guardian implant is yet another milestone achievement for the technology,” Mr Kelly said.

“It reinforces our confidence in achieving our goals as we progress towards commercialisation of the world’s only implantable heart attack alert system.”

Hydrix has also announced it has completed the application to the Australian Therapeutic Goods Administration.

Subject to the approval process, the company expects to receive approval in the first half of 2022.

Hydrix has ended the day 9.68 per cent in the green with shares trading at 17 cents in a $25.23 million market cap.

HYD by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.